600513 联环药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)4.61010.30311.66110.66010.000
总资产报酬率 ROA (%)2.1754.8475.5775.3975.230
投入资产回报率 ROIC (%)2.8346.4167.4617.3236.795

边际利润分析
销售毛利率 (%)50.97448.13753.34854.63153.837
营业利润率 (%)7.7478.0399.5679.49310.332
息税前利润/营业总收入 (%)8.7579.22310.71810.80011.436
净利润/营业总收入 (%)6.4536.9618.5138.5008.669

收益指标分析
经营活动净收益/利润总额(%)104.35890.236100.86797.45297.813
价值变动净收益/利润总额(%)-5.624-0.241-1.514-0.941-0.551
营业外收支净额/利润总额(%)-0.2110.1491.0612.087-0.877

偿债能力分析
流动比率 (X)0.9851.0861.1001.1821.292
速动比率 (X)0.7090.8330.8760.9831.055
资产负债率 (%)47.27946.86747.92845.60442.315
带息债务/全部投入资本 (%)38.76937.12337.35133.651--
股东权益/带息债务 (%)156.529167.777166.714196.041255.885
股东权益/负债合计 (%)99.290101.18097.342107.845123.586
利息保障倍数 (X)8.5287.87110.2249.7729.577

营运能力分析
应收账款周转天数 (天)81.78280.90880.47783.8130.000
存货周转天数 (天)112.42994.95995.11695.8370.000